Clinical-stage psychedelic medicine and biotech company Mind Medicine Inc MMEDF, also known as MindMed, is surging again Monday ahead of its Nasdaq debut.
The company's mission is "to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness," according to CEO J.R. Rahn.
Mind Medicine announced last Friday it will be uplisted to the Nasdaq on Tuesday, leading to a 40% rise in share price.
“The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company,” Rahn said in a press release. "We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value."
See Also: How MindMed Uses Tech To Innovate, Deploy Psychedelic Mental Health Therapies
Trading will begin Tuesday on the Nasdaq under the new ticker symbol "MNMD." Rahn will appear on Benzinga's "Power Hour" show Thursday afternoon.
MindMed's stock is up another 36% to $4.80 at the time of publication.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
